These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 32522525)

  • 1. The c-MET oncoprotein: Function, mechanisms of degradation and its targeting by novel anti-cancer agents.
    Park KC; Richardson DR
    Biochim Biophys Acta Gen Subj; 2020 Oct; 1864(10):129650. PubMed ID: 32522525
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Thiosemicarbazones suppress expression of the c-Met oncogene by mechanisms involving lysosomal degradation and intracellular shedding.
    Park KC; Geleta B; Leck LYW; Paluncic J; Chiang S; Jansson PJ; Kovacevic Z; Richardson DR
    J Biol Chem; 2020 Jan; 295(2):481-503. PubMed ID: 31744884
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cbl-independent degradation of Met: ways to avoid agonism of bivalent Met-targeting antibody.
    Lee JM; Kim B; Lee SB; Jeong Y; Oh YM; Song YJ; Jung S; Choi J; Lee S; Cheong KH; Kim DU; Park HW; Han YK; Kim GW; Choi H; Song PH; Kim KA
    Oncogene; 2014 Jan; 33(1):34-43. PubMed ID: 23208509
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The renaissance of polypharmacology in the development of anti-cancer therapeutics: Inhibition of the "Triad of Death" in cancer by Di-2-pyridylketone thiosemicarbazones.
    Jansson PJ; Kalinowski DS; Lane DJ; Kovacevic Z; Seebacher NA; Fouani L; Sahni S; Merlot AM; Richardson DR
    Pharmacol Res; 2015 Oct; 100():255-60. PubMed ID: 26318762
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Copper and conquer: copper complexes of di-2-pyridylketone thiosemicarbazones as novel anti-cancer therapeutics.
    Park KC; Fouani L; Jansson PJ; Wooi D; Sahni S; Lane DJ; Palanimuthu D; Lok HC; Kovačević Z; Huang ML; Kalinowski DS; Richardson DR
    Metallomics; 2016 Sep; 8(9):874-86. PubMed ID: 27334916
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting the hepatocyte growth factor/Met pathway in cancer.
    De Silva DM; Roy A; Kato T; Cecchi F; Lee YH; Matsumoto K; Bottaro DP
    Biochem Soc Trans; 2017 Aug; 45(4):855-870. PubMed ID: 28673936
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting the MET gene for the treatment of non-small-cell lung cancer.
    Gelsomino F; Facchinetti F; Haspinger ER; Garassino MC; Trusolino L; De Braud F; Tiseo M
    Crit Rev Oncol Hematol; 2014 Feb; 89(2):284-99. PubMed ID: 24355409
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Proteasomal and lysosomal degradation for specific and durable suppression of immunotherapeutic targets.
    Wang Y; Deng S; Xu J
    Cancer Biol Med; 2020 Aug; 17(3):583-598. PubMed ID: 32944392
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Shedding-generated Met receptor fragments can be routed to either the proteasomal or the lysosomal degradation pathway.
    Ancot F; Leroy C; Muharram G; Lefebvre J; Vicogne J; Lemiere A; Kherrouche Z; Foveau B; Pourtier A; Melnyk O; Giordano S; Chotteau-Lelievre A; Tulasne D
    Traffic; 2012 Sep; 13(9):1261-72. PubMed ID: 22672335
    [TBL] [Abstract][Full Text] [Related]  

  • 10. EORTC-NCI-AACR--20th symposium molecular targets and cancer therapeutics: mechanisms of targeting for cancer treatment.
    Fakorede A
    IDrugs; 2008 Dec; 11(12):857-8. PubMed ID: 19051142
    [No Abstract]   [Full Text] [Related]  

  • 11. Preclinical and clinical evaluation of MET functions in cancer cells and in the tumor stroma.
    Finisguerra V; Prenen H; Mazzone M
    Oncogene; 2016 Oct; 35(42):5457-5467. PubMed ID: 26996670
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting the c-MET signaling pathway for cancer therapy.
    Liu X; Yao W; Newton RC; Scherle PA
    Expert Opin Investig Drugs; 2008 Jul; 17(7):997-1011. PubMed ID: 18549337
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 1,2,4-Oxadiazole derivatives targeting EGFR and c-Met degradation in TKI resistant NSCLC.
    Dokla EME; Fang CS; Abouzid KAM; Chen CS
    Eur J Med Chem; 2019 Nov; 182():111607. PubMed ID: 31446247
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recent advances in the discovery of small molecule c-Met Kinase inhibitors.
    Parikh PK; Ghate MD
    Eur J Med Chem; 2018 Jan; 143():1103-1138. PubMed ID: 29157685
    [TBL] [Abstract][Full Text] [Related]  

  • 15. From concept to reality: the long road to c-Met and RON receptor tyrosine kinase inhibitors for the treatment of cancer.
    Dussault I; Bellon SF
    Anticancer Agents Med Chem; 2009 Feb; 9(2):221-9. PubMed ID: 19199866
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oncogene addiction as a foundation of targeted cancer therapy: The paradigm of the MET receptor tyrosine kinase.
    Orlando E; Aebersold DM; Medová M; Zimmer Y
    Cancer Lett; 2019 Feb; 443():189-202. PubMed ID: 30550851
    [TBL] [Abstract][Full Text] [Related]  

  • 17. c-MET kinase inhibitors: a patent review (2011 - 2013).
    Zhu K; Kong X; Zhao D; Liang Z; Luo C
    Expert Opin Ther Pat; 2014 Feb; 24(2):217-30. PubMed ID: 24266843
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In Vitro and In Vivo Activity of AMG 337, a Potent and Selective MET Kinase Inhibitor, in MET-Dependent Cancer Models.
    Hughes PE; Rex K; Caenepeel S; Yang Y; Zhang Y; Broome MA; Kha HT; Burgess TL; Amore B; Kaplan-Lefko PJ; Moriguchi J; Werner J; Damore MA; Baker D; Choquette DM; Harmange JC; Radinsky R; Kendall R; Dussault I; Coxon A
    Mol Cancer Ther; 2016 Jul; 15(7):1568-79. PubMed ID: 27196782
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The multiple paths towards MET receptor addiction in cancer.
    Duplaquet L; Kherrouche Z; Baldacci S; Jamme P; Cortot AB; Copin MC; Tulasne D
    Oncogene; 2018 Jun; 37(24):3200-3215. PubMed ID: 29551767
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeted Protein Degradation: An Emerging Therapeutic Strategy in Cancer.
    Barghout SH
    Anticancer Agents Med Chem; 2021; 21(2):214-230. PubMed ID: 32275492
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.